Adolor Corporation (NASDAQ:ADLR) is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products. The Company's first product, ENTEREG® (alvimopan) was approved by the FDA and launched with Glaxo Group Limited in mid-2008. ENTEREG is indicated to accelerate the time to upper and lower gastrointestinal (GI) recovery following partial large or small bowel resection surgery with primary anastomosis. For more information on ENTEREG, including its full prescribing information, visit www.ENTEREG.com.
The Company’s research and development pipeline includes: two novel delta opioid receptor agonists, currently in mid-stage clinical development in collaboration with Pfizer Inc. for chronic pain; a peripheral mu opioid receptor antagonist entering development for chronic opioid bowel dysfunction (OBD); and several opioid and non-opioid discovery programs.
Adolor is:
-Committed to innovation, focused on invention
-Driven by imagination to meet unmet medical needs in pain management
Company Details
- Employees
- 22
- Founded
- -
- Phone
- 17818601407
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- adolor.com
- Keywords
- New York.
Adolor Questions
Adolor's helpline number is 17818601407
Adolor's website is adolor.com
Adolor's LinkedIn profile is https://www.linkedin.com/company/adolor
Adolor has
22 employees.
View email and phone details for 22
employees at Adolor.
Adolor's industry is
Pharmaceutical Manufacturing
Adolor's top competitors are
Emergent Biosolutions,
Gsk,
River Vision Development Corp.,
Teva Pharmaceuticals,
Medexus Pharmaceuticals,
Cephalon,
Aptevo Therapeutics Inc,
Scopserv International Inc.,
Adolore Biotherapeutics,
Endo.
Adolor's categories are Pharmaceutical Manufacturing
Adolor's founding year is 1993
